Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF TSX Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-03-07 Management Reports
Country CA Canada
Listing TSX PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company specializing in incision-free ablative therapies. Its core product is TULSA-PRO®, a therapeutic platform designed for the treatment of localized prostate cancer, radiorecurrent prostate cancer, and benign prostatic hyperplasia (BPH). TULSA-PRO utilizes a robotically controlled, transurethral ultrasound ablation procedure guided by real-time Magnetic Resonance (MR) imaging. This system employs closed-loop temperature feedback to ensure precise and customizable tissue ablation, prioritizing patient safety and minimizing complications. The technology merges MR imaging, thermal ultrasound, and robotics to offer a durable and accurate treatment delivery method.

Recent filings

Filing Released Lang Actions
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the years ended December 31, 2023 and 2022, prepared as of March 7, 2024. It references audited consolidated financial statements prepared under IFRS and discusses detailed business overview, forward-looking statements, risks, and operational details. The MD&A is a detailed management report explaining financial results, business trends, and outlook, which aligns with the definition of Management Reports (MDA). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. There is no indication that this is an Annual Report (10-K) or an Interim Report (IR), as it focuses on management's discussion rather than full financial statements. Therefore, the correct classification is Management Reports (MDA).
2024-03-07 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 100% confidence The document is a Form 13-502F1 submission to the Ontario Securities Commission, which is a regulatory filing related to participation fees for reporting issuers. It includes a management certification by the CFO, market value calculations for quarterly trading periods, and fee calculations. There are no financial statements, earnings data, or detailed management discussion. The document is primarily a certification and fee calculation form submitted to a regulatory body, fitting the criteria for a Regulatory Filing (RNS) rather than a full financial report or other specific filing types.
2024-03-07 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1, which is a management certification related to participation fees for reporting issuers, submitted to the Alberta Securities Commission. It includes certification by a company officer (CFO) confirming the accuracy of the information. The content focuses on market value calculations and fee payments rather than financial results or detailed financial statements. The document is short (4505 characters) and primarily a certification form rather than a financial report or announcement. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory submission and officer certification, not a full financial report or announcement of a report.
2024-03-07 English
Audited annual financial statements – English.pdf
Annual Report Classification · 100% confidence The document contains detailed consolidated financial statements for Profound Medical Corp. for the years ended December 31, 2023 and 2022, including balance sheets, statements of loss and comprehensive loss, statements of changes in shareholders' equity, and cash flows. It also includes the report of the independent registered public accounting firm (auditor's report) expressing an opinion on the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial data, notes to the financial statements, and the auditor's opinion aligns with the characteristics of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or certification, so it is not classified as RPA or RNS. Therefore, the document is best classified as an Annual Report (10-K). FY 2023
2024-03-07 English
News release - English.pdf
Annual Report Classification · 95% confidence The document is a detailed announcement of Profound Medical Corp.'s financial results for the fourth quarter and full year ended December 31, 2023. It includes comprehensive financial data such as revenue, operating expenses, net loss, balance sheet items, and detailed business highlights. The presence of full financial statements and substantive financial analysis indicates this is a formal financial report rather than a brief earnings release or a simple announcement. The document also references the fiscal year-end and provides detailed management commentary on financial performance and business developments. Therefore, this document fits the definition of an Annual Report (10-K) or equivalent annual financial report. Given the detailed financial results for the full year and quarter, and the comprehensive nature of the report, the appropriate classification is Annual Report (10-K). FY 2023
2024-03-07 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed offering description for conditional coupon notes linked to the S&P 500 index issued by La Banque de Nouvelle-Écosse. It includes terms such as coupon payments, early redemption conditions, capital protection, subscription minimums, CUSIP, and other investment details. The text is a prospectus or offering memorandum for a structured financial product, describing the terms and conditions of the notes. It is not a financial report, earnings release, management discussion, or regulatory filing. It is also not an announcement of a report but the actual offering document. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to the issuance and terms of a new financial instrument or capital raising product.
2024-03-04 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.